<?xml version="1.0" encoding="UTF-8"?>
<p>Over the last 20 years, three coronaviruses (CoVs) that cause severe pulmonary infections in humans have crossed the species barrier.
 <xref rid="rmv2143-bib-0001" ref-type="ref">
  <sup>1</sup>
 </xref>, 
 <xref rid="rmv2143-bib-0002" ref-type="ref">
  <sup>2</sup>
 </xref> The last of these CoVs, named SARS‐CoV‐2, emerged in the Hubei province (China) in December 2019, and rapidly spread worldwide becoming a major public health threat.
 <xref rid="rmv2143-bib-0003" ref-type="ref">
  <sup>3</sup>
 </xref> In approximately 20% of patients, the disease progresses to severe pneumonia, respiratory and multi‐visceral failure, often leading to death of patients with comorbidity.
 <xref rid="rmv2143-bib-0004" ref-type="ref">
  <sup>4</sup>
 </xref> This worsening is associated with a deregulated immune response, including exacerbated production of pro‐inflammatory cytokines.
 <xref rid="rmv2143-bib-0005" ref-type="ref">
  <sup>5</sup>
 </xref> Therefore, specific and effective antiviral therapies are urgently needed, due to the absence of a vaccine.
</p>
